Definition

• Simple (total) hysterectomy — uterus removed, adnexa preserved
• Supracervical hysterectomy — corpus removed, cervix left in situ
• Radical hysterectomy — uterus + parametria + upper vaginal cuff removed (for malignancy)

"A hysterectomy is performed through a transverse suprapubic incision. During the procedure tremendous care is taken to identify the distal ureters and to ligate the nearby uterine arteries without damage to the ureters." — Gray's Anatomy for Students

Indications

Gynecologic Malignancy (Primary indication for BSO)

• Endometrial cancer — staging laparotomy requires TAH-BSO + omentectomy + lymph node dissection
• Ovarian cancer — BSO is part of cytoreductive surgery
• Cervical cancer — radical hysterectomy ± BSO
• Uterine leiomyosarcoma — TAH with bilateral oophorectomy indicated

Benign Conditions (Hysterectomy ± selective BSO)

Prophylactic BSO Indications

• BRCA1/BRCA2 mutation carriers — lifetime ovarian cancer risk 10–50%; risk-reducing BSO recommended (after age 35–40)
• Lynch II syndrome — prophylactic hysterectomy with BSO is effective primary prevention

Important: In premenopausal women at average risk for ovarian cancer, ovarian conservation is recommended — prophylactic BSO before age 55 is associated with an 8.58% excess mortality by age 80 (predominantly cardiovascular) and offers no overall survival benefit. — Berek & Novak's Gynecology

Preoperative Considerations

• Informed consent documenting options, risks, benefits, alternatives, and personnel
• Document completion of childbearing; sterilization consent forms required in most jurisdictions
• Health assessment: Correct underlying anemia preoperatively (iron supplementation or GnRH agonists reduce blood product use)
• VTE risk stratification: Age, BMI, thrombophilia, smoking, hormone use
• Imaging: Pelvic ultrasound; CT/MRI for malignancy staging
• Bowel prep: No longer routinely required
• Prophylactic antibiotics: Standard of care (cephalosporin, 1 hour preoperatively)

Route Selection

• Cardiopulmonary disease precluding pneumoperitoneum or general anesthesia
• Known/suspected uterine malignancy where morcellation is required
• Severely distorted anatomy from disease or adhesions making minimally invasive surgery unsafe
• No surgeon access to laparoscopic/vaginal expertise

Minimally invasive hysterectomy (laparoscopic or vaginal) is preferred for benign disease when feasible, with lower complication rates, less pain, faster recovery, and similar or lower hospital readmission rates.

Surgical Anatomy Relevant to TAH-BSO

• Ureters — cross beneath the uterine artery ("water under the bridge") at the lateral cervix; must be identified before ligation of uterine vessels
• Uterine arteries — arise from internal iliac arteries; ligated at the cervicouterine junction
• Infundibulopelvic (IP) ligament — contains ovarian vessels (from aorta/renal vein); ligated to remove the adnexa
• Cardinal ligament (Mackenrodt's ligament) — provides primary uterine support; serially clamped and ligated
• Uterosacral ligaments — support posterior uterus; incorporate into vaginal cuff closure for apical support
• Bladder — mobilized anteriorly off the lower uterine segment and cervix

Surgical Technique: Step-by-Step

Access and Exposure

1. Abdominal incision: Low transverse (Pfannenstiel) for benign disease and smaller uteri; vertical midline for malignancy, large pathology, poor visualization, or anticipated extensive surgery
2. Exploration: Upper abdomen examined for extrapelvic disease; suitable retractor (e.g., Bookwalter) placed
3. Uterus grasped at both cornua with Kocher clamps and elevated into the incision

Key Steps

Steps D–F: Division of ovarian vessels (BSO), salpingectomy, and utero-ovarian vessel division — Sabiston Textbook of Surgery

Incision of the anterior and posterior broad ligament

Serial clamping and division of the cardinal ligament

• Heaney transfixion stitches at lateral vaginal corners (incorporating the ipsilateral uterosacral ligament for apical support)
• The colpotomy is closed with running, interrupted, or figure-of-eight absorbable sutures
• Pelvic reperitonization is not routinely necessary

Complications

Intraoperative

Postoperative

Long-term Sequelae of BSO in Premenopausal Women

• Surgical menopause — abrupt estrogen withdrawal; hot flashes, sleep disturbance, vaginal atrophy
• Increased cardiovascular risk — especially if BSO before age 50 without HRT
• Osteoporosis — accelerated bone loss
• Sexual dysfunction — reduced libido, dyspareunia
• Cognitive effects — possible increased dementia risk (controversial)
• Hormone replacement therapy (HRT) should be strongly considered in women under 50 undergoing BSO for benign conditions

Perioperative Care

Preoperative

• NPO after midnight; IV access
• Antibiotic prophylaxis (cefazolin 2g IV, or 3g if >120 kg) within 60 min of incision
• DVT prophylaxis initiated preoperatively
• Foley catheter placed in OR

Intraoperative

• Regional (epidural T8–T11) or general anesthesia
• Patient supine; modified Trendelenburg to displace bowel
• Normothermia maintained

Postoperative

• Foley catheter: Remove within 24 hours when not anticipated to have spontaneous voiding difficulty
• Diet: Advance as tolerated; no evidence for dietary restriction
• Analgesia: NSAIDs (e.g., diclofenac reduces postoperative morphine consumption), acetaminophen, opioids as needed
• Early mobilization: Key for VTE prevention and GI recovery
• Hospital stay: 2–4 days typical for open TAH
• Return to activity: 4–6 weeks for full return; pelvic rest (no intercourse) for 6–8 weeks until vaginal cuff healed

Route Comparison (TAH vs. Minimally Invasive)

A 2023 Cochrane systematic review (PMID 37642285) confirmed that laparoscopic/vaginal hysterectomy is associated with better short-term outcomes than open TAH for benign disease. A 2023 meta-analysis (PMID 37856058) found robotic-assisted hysterectomy comparable to laparoscopic in outcomes.

Key Points Summary

1. TAH-BSO removes uterus, cervix, both fallopian tubes, and both ovaries via laparotomy
2. Primary indications include gynecologic malignancy, and selected benign conditions refractory to conservative therapy
3. Ureter identification at the IP ligament and at the level of the uterine artery is the most critical step to prevent the most feared intraoperative complication
4. BSO in premenopausal women at average ovarian cancer risk carries excess long-term mortality; HRT should be offered post-operatively
5. Open TAH is now reserved for cases where minimally invasive approaches are unsafe or unavailable
6. Common postoperative complications include vault infection, VTE, VVF, and ileus

• Indications — separated into malignant (where BSO is mandatory) vs. benign (where ovarian conservation decisions are nuanced), plus prophylactic BSO for high-risk genetics
• Surgical technique — step-by-step with intraoperative images from Sabiston and Schwartz's showing the key pedicle divisions
• Complications — organized intraoperatively vs. postoperatively, including the long-term hormonal sequelae unique to BSO in premenopausal women
• Perioperative care — covers the full continuum from NPO to discharge to activity restrictions
• Route comparison — contextualizes when open TAH remains appropriate vs. minimally invasive alternatives, supported by the 2023 Cochrane review

Bartholin Cyst (Bartholin Duct Cyst & Abscess)

Anatomy

Pathophysiology

"Obstruction of the duct may result in a cyst or abscess. A cyst does not need to be present before an abscess can develop." — Tintinalli's Emergency Medicine

Epidemiology

• Occur at all ages, predominantly in reproductive-age women
• Bartholin abscesses affect approximately 2% of women
• Uncommon after menopause (gland involutes); any Bartholin gland mass in a woman >40 years must raise suspicion for malignancy

Microbiology (Abscess)

Clinical Features

Bartholin Duct Cyst

• Unilateral, smooth, fluctuant mass at the posterior vestibule (4 or 8 o'clock)
• Often asymptomatic if small
• Larger cysts cause local pressure, discomfort, dyspareunia
• No erythema or warmth (unless infected)

Bartholin Abscess

• Rapidly enlarging, extremely painful mass at same location
• Induration, erythema, fluctuance
• Patient may have difficulty walking or sitting
• Systemic symptoms (fever, chills) are rarely present — their absence does not exclude an abscess
• Develops over several days (or longer if preceded by a cyst)

Diagnosis

• Characteristic location at posterior introitus (labia minora transecting the mass)
• Fluctuance confirms abscess

Caution: Distinguish a Bartholin abscess from an abscess of the labia majora, which requires gynecologic consultation. Any solid component or atypical appearance in a woman >40 warrants biopsy to exclude carcinoma.

Treatment

1. Asymptomatic Cyst

• No treatment required — observation is appropriate for small, asymptomatic cysts

2. Symptomatic Cyst or Abscess — First-line: Word Catheter

1. Patient in dorsal lithotomy position; identify abscess at 5 or 7 o'clock with labia minora transecting it
2. Analgesia: 2–4 mL 1% lidocaine infiltrated through the mucosal surface (not skin surface); IV opioids/procedural sedation for severe pain
3. #11 scalpel — stab incision on the mucosal surface of the vestibule, just lateral to the hymenal ring, where fluctuance is maximal. Incision must be large enough for catheter, but not so large the balloon is displaced
4. Alternatively: stabilize abscess with thumb/index finger and "skewer" onto a hemostat for entry
5. Drain pus (expect a palpable pop and free flow of pus); insert Word catheter to the hilt
6. Inflate balloon with 2–4 mL saline; tuck catheter end into vagina
7. Catheter remains in place 4–6 weeks to allow epithelialization of a new permanent duct opening
8. Send pus for culture (including MRSA, GC, chlamydia)
9. Prescribe analgesics; antibiotics after drainage are of no proven value routinely (cover GC/CT if suspected)

3. Recurrent Cyst/Abscess — Marsupialization

1. Patient in dorsal lithotomy; local anesthetic (2% lidocaine ± epinephrine) or pudendal block
2. Retract labium laterally; identify incision site internal to the hymenal ring (mucosa, not skin)
3. Longitudinal fusiform incision 1–2 cm wide over the cyst wall; excise an ellipse of mucosa
4. Grasp cyst wall with two hemostats before segment is removed; cyst will decompress
5. Break up any loculations with small hemostats; irrigate with normal saline
6. In patients >40 years: inspect interior for neoplastic-appearing epithelium; send for biopsy
7. Suture cyst wall edge to adjacent vaginal mucosa with interrupted 4-0 Vicryl — this is the marsupialization step, suturing the cavity open permanently
8. Minimum gap of ≥1 cm across the open marsupialization
9. No dressing required; sitz baths daily for 3–4 days

4. Failed/Persistent Cases — Complete Gland Excision

• Technically more demanding; risks include hemorrhage and hematoma
• A common surgical error is making the incision on the lateral vulvar skin rather than the vestibular mucosa

CPT / Procedure Codes

Bartholin Gland Carcinoma

• Squamous cell carcinoma (most common)
• Adenocarcinoma
• Adenoid cystic carcinoma (characteristically slow-growing, perineural invasion)
• Transitional cell carcinoma

Special Considerations

Summary Algorithm

Bartholin lesion
     │
     ├── Asymptomatic cyst → Observe
     │
     ├── Symptomatic cyst or abscess (1st episode)
     │         → Word catheter (4–6 weeks)
     │
     ├── Recurrent cyst/abscess
     │         → Marsupialization
     │
     ├── Failed marsupialization / persistent
     │         → Complete gland excision
     │
     └── Solid mass / age >40 / postmenopausal
               → Biopsy to exclude carcinoma